Patent Court Loss Erases Half of Liquidia's Value, but Appeal Process Opens Path to Partial Recovery

Liquidia's stock plummeted 57% after a Delaware court ruled that its Yutrepia drug infringes United Therapeutics' treprostinil patent for pulmonary hypertension with interstitial lung disease treatment. The company plans to appeal the decision and request FDA label modifications to remove the disputed indication, while United Therapeutics seeks an injunction and damages. Despite the dramatic single-day collapse, valuation models suggest the stock could recover to $59 within four years if the remedy proves limited, as the appeal and label-stripping strategy remain viable paths forward.

Liquidia's Yutrepia received regulatory approval to treat pulmonary hypertension in patients with interstitial lung disease, a serious respiratory condition. The Delaware court found that two specific patent claims held by competitor United Therapeutics covered this exact treatment approach, determining that Liquidia's drug formulation and method of delivery infringed those protected claims. The company now faces potential restrictions on how—or whether—it can market and sell Yutrepia for this indication.

Liquidia's strategy centers on two parallel efforts: requesting that the FDA remove the disputed indication from Yutrepia's label and simultaneously appealing the court's decision. This approach could limit financial exposure by narrowing the drug's approved uses while the legal challenge proceeds. The ultimate financial impact depends heavily on the scope of any injunction the court imposes and whether the appeals process yields a different outcome.